Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-[alpha] with BCAR1 and Traf6

The effects of estrogen on osteoclast survival and differentiation were studied using CD14-selected mononuclear osteoclast precursors from peripheral blood. Estradiol at ~1 nM reduced RANKL-dependent osteoclast differentiation by 40-50%. Osteoclast differentiation was suppressed 14 days after addition of RANKL even when estradiol was withdrawn after 18 h. In CD14+ cells apoptosis was rare and was not augmented by RANKL or by 17-[beta]-estradiol. Estrogen receptor-[alpha] (ER[alpha]) expression was strongly down-regulated by RANKL, whether or not estradiol was present. Mature human osteoclasts thus cannot respond to estrogen via ER[alpha]. However, ER[alpha] was present in CD14+ osteoclast progenitors, and a scaffolding protein, BCAR1, which binds ER[alpha] in the presence of estrogen, was abundant. Immunoprecipitation showed rapid (~5 min) estrogen-dependent formation of ER[alpha]-BCAR1 complexes, which were increased by RANKL co-treatment. The RANKL-signaling intermediate Traf6, which regulates NF-[kappa]B activity, precipitated with this complex. Reduction of NF-[kappa]B nuclear localization occurred within 30 min of RANKL stimulation, and estradiol inhibited the phosphorylation of I[kappa]B in response to RANKL. Inhibition by estradiol was abolished by siRNA knockdown of BCAR1. We conclude that estrogen directly, but only partially, curtails human osteoclast formation. This effect requires BCAR1 and involves a non-genomic interaction with ER[alpha]. [PUBLICATION ABSTRACT]